About Dewpoint Therapeutics
Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable.
|
|
|
51-200 employees
View all Dewpoint Therapeutics employees
|
|
Biotechnology
|
|
451 D Street, Suite 104, Boston, MA 02210, US
|
|
2018
|
|
Oncology, Virology, Insulin Resistance, Neurodegeneration, Rare Disease, Cardiopulmonary, Biomolecular Condensates
|
Dewpoint Therapeutics Alternatives
Frequently Asked Questions about Dewpoint Therapeutics
Sandra Kleinstuck is the CEO of Dewpoint Therapeutics.
The decision makers in Dewpoint Therapeutics are Ameet Nathwani, Amir Nashat, Kelly Clark, etc. Click to Find Dewpoint Therapeutics decision makers emails.
Dewpoint Therapeutics Staff Directory
Search Dewpoint Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
